We recently completed proof of concept studies with a recombinant fusion protein that activates the TRAIL death signaling pathway in leukemia cells at femtomolar concentrations. The work was published today in the Journal of Clinical Investigation.
http://www.jci.org/articles/view/76610
http://www.jci.org/articles/view/76610